Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Company Announcements

Dr. Reddy’s Laboratories Reports Q2 Revenue Growth

Dr Reddy’s Laboratories (RDY) has released an update.

Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong growth in global generics and emerging markets. Despite the rise in revenues, the company faced a decline in profit after tax attributable to equity holders, which fell by 15% year-over-year. The Board also approved a significant investment in its Russian subsidiary to support working capital needs, reflecting its ongoing commitment to strengthening core businesses and expanding market presence.

For further insights into RDY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskDr. Reddy’s Announces New Employee Stock Options
TheFlyJourney Medical announces U.S. FDA approval of Emrosi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App